Nowadays more and more organizations and governments are starting to acknowledge AMR and act on the problem. A few years ago, the WHO also published the priority pathogen list, which includes 12 pathogens that are (multi-)drug resistant, require long hospitalization, and are generally hard to treat. The goal of this list is to spur R&D into the development of novel treatments, antibiotics, and diagnostics in infectious disease and AMR. Without this incentive (leaving it to market forces alone), advances in the government-funded sector as well as the funded sector are just too slow.
The notion is that with more global awareness and funds specifically dedicated to AMR research, this necessary field can gain the needed interest and popularity to accelerate the development of novel treatments and ensure AMR preparedness.
As a company working in this field, we are extremely happy with the increasing awareness, as this will make it easier for us to implement change and help ensure healthcare all over the world.
Sources/further reading:
